1Jackson K, Payne CD, Chua L, et al. The effect of successfully treating plaque psoriasis with ixekizumab on the pharmacokinetics of cytochrome P450 substrates. Poster presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 13-16, 2019; Washington, D.C.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. ClinPharmacolTher. 2009;85(4):434-438. http://dx.doi.org/10.1038/clpt.2008.302
4Wang J, Wang YMC, Ahn HY. Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J. 2014;16(5):938-947. http://dx.doi.org/10.1208/s12248-014-9637-0